Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

88.48 +1.27 (+1.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 53,258
Open 86.66
Bid (Size) 66.00 (1)
Ask (Size) 139.53 (2)
Prev. Close 87.21
Today's Range 85.53 - 88.51
52wk Range 72.57 - 169.29
Shares Outstanding 16,676,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
From Ligand Pharmaceuticals Incorporated
Via Business Wire
10 Biggest Price Target Changes For Monday
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. 
Via Benzinga

Performance

YTD
-41.62%
-41.62%
1 Month
-0.48%
-0.48%
3 Month
-26.75%
-26.75%
6 Month
-43.89%
-43.89%
1 Year
-35.66%
-35.66%

More News

Read More
Ligand Reports First Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report First Quarter Financial Results on May 4
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Earnings Scheduled For February 17, 2022
Via Benzinga
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger
Via Benzinga
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tough Slogging Ahead for Investors, Diversification is Important
Via Talk Markets
Recap: Ligand Pharmaceuticals Q4 Earnings
Via Benzinga
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Via Benzinga
Ligand to Report Fourth Quarter Financial Results on February 17
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand and GSK Expand Global Collaboration and License Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Meme Stock Breakdown
Via Talk Markets
Ligand Pharmaceuticals Sees RS Rating Rise To 92
Via Investor's Business Daily
Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company
Via Benzinga
Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Ligand Pharmaceuticals Q3 Earnings
Via Benzinga
Ligand Reports Third Quarter 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.